T. Rowe Price Investment Management, Inc. Apellis Pharmaceuticals, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $166 Billion
- Q3 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 2,985,272 shares of APLS stock, worth $86.5 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
2,985,272
Previous 4,048,412
26.26%
Holding current value
$86.5 Million
Previous $155 Million
44.56%
% of portfolio
0.05%
Previous 0.1%
Shares
9 transactions
Others Institutions Holding APLS
# of Institutions
308Shares Held
115MCall Options Held
3.85MPut Options Held
1.09M-
Wellington Management Group LLP Boston, MA15.6MShares$451 Million0.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$345 Million14.88% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$322 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$285 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$168 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.18B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...